Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 USD | +1.35% | -0.24% | -44.77% |
05-22 | HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating | MT |
05-14 | Acelyrin, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.77% | 408M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.49% | 21.96B | |
-8.63% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- SLRN Stock
- News Acelyrin, Inc.
- ACELYRIN Flags 'Clinical Execution Errors' in Hidradenitis Suppurativa Trials Involving Contract Research Organization